[The use of passive rabies immunotherapy: from the past to the future]
Autor: | Bourhy, Hervé, Dacheux, Laurent, Ribadeau-Dumas, Florence |
---|---|
Přispěvatelé: | Centre National de Référence de la Rage-Dynamique des Lyssavirus et adaptation à l'hôte (CNR), Institut Pasteur [Paris], Centre Collaborateur de l'OMS pour la Rage - Dynamique des lyssavirus et adaptation à l'hôte (CC-OMS) |
Jazyk: | francouzština |
Rok vydání: | 2010 |
Předmět: |
History
MESH: Immune Tolerance Rabies Passive History 21st Century MESH: Rabies Immune Tolerance Animals Humans MESH: Animals Horses MESH: Horses MESH: Developing Countries Developing Countries 19th Century MESH: Humans Immunization Passive MESH: Rabies Vaccines History 19th Century History 20th Century 21st Century MESH: Rabies virus 20th Century Rabies Vaccines Rabies virus [SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology MESH: History 19th Century Immunization MESH: Immunization Passive MESH: History 20th Century Horse Diseases MESH: History 21st Century MESH: Horse Diseases |
Zdroj: | Biologie Aujourd'hui Biologie Aujourd'hui, EDP sciences, 2010, 204 (1), pp.71-80. ⟨10.1051/jbio/2009049⟩ |
ISSN: | 2105-0678 2105-0686 |
DOI: | 10.1051/jbio/2009049⟩ |
Popis: | International audience; Rabies is a fatal disease transmitted by infected animals by bite, scratch, licking on broken skin or contamination of mucosis by saliva. The regimen of post-exposure prophylaxis for people not previously vaccinated, that is currently recommended by WHO, consists of a combination of wound cleaning, active immunization and passive immunization when the exposure is of category 3. Most of the products available on the market, in particular human rabies immunoglobulins, highly purified equine rabies immunoglobulins and the derived F(ab')(2) fragments, are now characterized by high potency and safety. Although the interest of passive anti-rabies immunization was first demonstrated in the first half of the 20th century, there is still an inadequate supply of these products to the target populations mostly in developing countries. Therefore, it is urgent to set-up training and information actions for healthcare personnel on the need to use passive immunotherapy and the lack of adverse effects of the related products. For the future, we hope that a scale up of production and a lower price will improve the accessibility to these products. The development of new products based on monoclonal antibodies and molecular biology, and which may be cheaper, is promising. |
Databáze: | OpenAIRE |
Externí odkaz: |